The Prospective Comparison of angiotensin receptor-neprilysin inhibitor with ACEI to determine the impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF) study assessed the combination drug ARB valsartan with neprilysin inhibitor sacubitril (LCZ 696) versus enalapril which showed significantly reduced mortality in patients with heart failure with reduced ejection fraction with a lower incidence of angioedema events compared to omapatrilat [48]. The gene discussed is MME; the disease is heart failure.